Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice
Open Access
- 3 September 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 1935
- https://doi.org/10.3389/fimmu.2018.01935
Abstract
Pemphigus vulgaris (PV) is a potentially life-threatening autoimmune blistering disease which is associated with autoantibodies directed against two desmosomal proteins, desmoglein (Dsg) 3 and 1. Treatment of PV is rather challenging and relies on the long-term use of systemic corticosteroids and additional immunosuppressants. More recently, autoantibody-depleting therapies such as rituximab, high-dose intravenous immunoglobulins, and immunoadsorption were shown to be valuable treatment options in PV. Specific removal of pathogenic autoantibodies would further increase efficacy and usability of immunoadsorption. Here, we tested the capacity of our recently developed prototypic Dsg1- and Dsg3-specific adsorbers to remove circulating pathogenic autoantibodies from three different PV patients. The pathogenic potential of the Dsg3/1-depleted IgG fractions and the anti-Dsg3-specific IgG was explored in two different in vitro assays based on cultured human keratinocytes, the desmosome degradation assay and the dispase-based dissociation assay. In addition, the neonatal mouse model of PV was used. In both in vitro assays, no difference between the pathogenic effect of total PV IgG and anti-Dsg3-specific IgG was seen, while Dsg3/1-depleted and control IgG were not pathogenic. For the samples of all 3 PV patients, depletion of anti-Dsg3/1 IgG resulted in a complete loss of pathogenicity when injected into neonatal mice. In contrast, injection of anti-Dsg3-specific IgG, eluted from the column, induced gross blistering in the mice. Our data clearly show that anti-Dsg3-specific IgG alone is pathogenic in vitro and in vivo, whereas Dsg3/1-depletion results in a complete loss of pathogenicity. Furthermore, our data suggest that Dsg-specific adsorption may be a suitable therapeutic modality to efficiently reduce pathogenic autoantibodies in patients with severe PV.Keywords
This publication has 55 references indexed in Scilit:
- Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blisteringJCI Insight, 2013
- An Adult Passive Transfer Mouse Model to Study Desmoglein 3 Signaling in Pemphigus VulgarisJournal of Investigative Dermatology, 2012
- Pemphigus autoimmunity: Hypotheses and realitiesAutoimmunity, 2011
- Desmosome Disassembly in Response to Pemphigus Vulgaris IgG Occurs in Distinct Phases and Can Be Reversed by Expression of Exogenous Dsg3Journal of Investigative Dermatology, 2011
- IgG Autoantibodies Against Desmocollin 3 in Pemphigus Sera Induce Loss of Keratinocyte AdhesionThe American Journal of Pathology, 2011
- Autoimmunity to Desmocollin 3 in Pemphigus VulgarisThe American Journal of Pathology, 2010
- Desmocollin 3-mediated Binding Is Crucial for Keratinocyte Cohesion and Is Impaired in PemphigusPublished by Elsevier BV ,2009
- Disruption of Desmosome Assembly by Monovalent Human Pemphigus Vulgaris Monoclonal AntibodiesJournal of Investigative Dermatology, 2009
- Loss of desmocollin 3 in mice leads to epidermal blisteringJournal of Cell Science, 2008
- Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG from Patients with the DiseaseThe New England Journal of Medicine, 1982